<code id='EA19BE88AB'></code><style id='EA19BE88AB'></style>
    • <acronym id='EA19BE88AB'></acronym>
      <center id='EA19BE88AB'><center id='EA19BE88AB'><tfoot id='EA19BE88AB'></tfoot></center><abbr id='EA19BE88AB'><dir id='EA19BE88AB'><tfoot id='EA19BE88AB'></tfoot><noframes id='EA19BE88AB'>

    • <optgroup id='EA19BE88AB'><strike id='EA19BE88AB'><sup id='EA19BE88AB'></sup></strike><code id='EA19BE88AB'></code></optgroup>
        1. <b id='EA19BE88AB'><label id='EA19BE88AB'><select id='EA19BE88AB'><dt id='EA19BE88AB'><span id='EA19BE88AB'></span></dt></select></label></b><u id='EA19BE88AB'></u>
          <i id='EA19BE88AB'><strike id='EA19BE88AB'><tt id='EA19BE88AB'><pre id='EA19BE88AB'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          entertainment

          author:focus    - browse:2
          Monica Bertagnolli -- health policy coverage from STAT
          NIH Director Monica Bertagnolli Kevin Dietsch/Getty Images

          WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally funded research — and now, in a major recent move, said he’ll trigger government “march-in” on patents for drugs that run afoul of that goal.

          “It’s a simple principle. You shouldn’t pay the highest price in the world for drugs that your tax dollars have already helped create,” Biden said last month as he touted the move at the National Institutes of Health.

          advertisement

          But the new NIH director, locked in the center of this debate, isn’t taking any big steps yet.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time